BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 27416045)

  • 1. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
    Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
    Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.
    Sandborn WJ; Bosworth B; Zakko S; Gordon GL; Clemmons DR; Golden PL; Rolleri RL; Yu J; Barrett AC; Bortey E; Paterson C; Forbes WP
    Gastroenterology; 2015 Apr; 148(4):740-750.e2. PubMed ID: 25644096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis.
    Rubin DT; Sandborn WJ; Bosworth B; Zakko S; Gordon GL; Sale ME; Rolleri RL; Golden PL; Barrett AC; Bortey E; Forbes WP
    Dig Dis Sci; 2015 Nov; 60(11):3408-17. PubMed ID: 26386854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis.
    Gross V; Bar-Meir S; Lavy A; Mickisch O; Tulassay Z; Pronai L; Kupcinskas L; Kiudelis G; Pokrotnieks J; Kovács A; Faszczyk M; Razbadauskas A; Margus B; Stolte M; Müller R; Greinwald R;
    Aliment Pharmacol Ther; 2006 Jan; 23(2):303-12. PubMed ID: 16393311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
    Naganuma M; Aoyama N; Tada T; Kobayashi K; Hirai F; Watanabe K; Watanabe M; Hibi T
    J Gastroenterol; 2018 Apr; 53(4):494-506. PubMed ID: 28779419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
    Rubin DT; Cohen RD; Sandborn WJ; Lichtenstein GR; Axler J; Riddell RH; Zhu C; Barrett AC; Bortey E; Forbes WP
    J Crohns Colitis; 2017 Jul; 11(7):785-791. PubMed ID: 28333362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical therapy is underused in patients with ulcerative colitis.
    Seibold F; Fournier N; Beglinger C; Mottet C; Pittet V; Rogler G;
    J Crohns Colitis; 2014 Jan; 8(1):56-63. PubMed ID: 23566922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
    Cortot A; Maetz D; Degoutte E; Delette O; Meunier P; Tan G; Cazals JB; Dewit O; Hebuterne X; Beorchia S; Grunberg B; Leprince E; D'Haens G; Forestier S; Idier I; Lémann M
    Am J Gastroenterol; 2008 Dec; 103(12):3106-14. PubMed ID: 19086960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.
    Naganuma M; Aoyama N; Suzuki Y; Nishino H; Kobayashi K; Hirai F; Watanabe K; Hibi T
    J Crohns Colitis; 2016 Jul; 10(7):828-36. PubMed ID: 26577683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
    Kruis W; Siegmund B; Lesniakowski K; Simanenkov V; Khimion L; Sobon M; Delmans G; Maksyashina SV; Sablin OA; Pokrotnieks J; Mostovoy Y; Datsenko O; Abdulkhakov S; Dorofeyev A; Levchenko O; Alexeeva O; Andreev P; Kolesnik IP; Mihaly E; Abrahamovych O; Baluta M; Kharchenko N; Viacheslav N; Uspenskiy Y; Vieth M; Mohrbacher R; Mueller R; Greinwald R
    J Crohns Colitis; 2022 Nov; 16(11):1714-1724. PubMed ID: 35709376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM; Kushkuley S; Barrett JA; Oster G
    Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
    Sandborn WJ; Travis S; Moro L; Jones R; Gautille T; Bagin R; Huang M; Yeung P; Ballard ED
    Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
    United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.
    Kruis W; Neshta V; Pesegova M; Alekseeva O; Andreev P; Datsenko O; Levchenko O; Abdulkhakov S; Lozynskyy Y; Mostovoy Y; Soloviev K; Dorofeyev AE; Vieth M; Stiess M; Greinwald R; Mohrbacher R; Siegmund B
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):98-106.e4. PubMed ID: 29702300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
    Sandborn WJ; Danese S; D'Haens G; Moro L; Jones R; Bagin R; Huang M; David Ballard E; Masure J; Travis S
    Aliment Pharmacol Ther; 2015 Mar; 41(5):409-18. PubMed ID: 25588902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis.
    Bar-Meir S; Fidder HH; Faszczyk M; Bianchi Porro G; Sturniolo GC; Mickisch O; Müller R; Greinwald R; Chowers Y; Grobeta V;
    Dis Colon Rectum; 2003 Jul; 46(7):929-36. PubMed ID: 12847368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
    Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
    J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study.
    Pokrotnieks J; Marlicz K; Paradowski L; Margus B; Zaborowski P; Greinwald R
    Aliment Pharmacol Ther; 2000 Sep; 14(9):1191-8. PubMed ID: 10971236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
    Sinha A; Nightingale J; West KP; Berlanga-Acosta J; Playford RJ
    N Engl J Med; 2003 Jul; 349(4):350-7. PubMed ID: 12878742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.